Results from phase 2b RESTORE trial of MCO-010 for treatment of retinitis pigmentosa
Keywords included in this article: retinitis pigementosa, RD, optogenetics, gene therapy, intravitrea, ophthalmology
Source: Retinitis Pigementosa affects more than 2 million people world wide. Currently there is no treatment to halt or reverse the condition. New gene therapies such as Multi-characteristic opsin (MCO)-10 are currently in trial and the results from the phase 2b trial show positive results.